Table 4

Therapy and mortality of patients with Pseudomonas aeruginosa producing metallo-β-lactamase hospital-acquired pneumonia

Treatment

Hospital-acquired pneumonia (n = 42)

Ventilator-associated pneumonia (n = 22)

Treated patients

30-day mortality (n = 24)

Treated patients

30-day mortality (n = 17)

Appropriate monotherapy

18 (42.9)

9 (50.0)

12 (54.5)

9 (75.0)

Aztreonam^a

8

2

3

2

Polymyxin B^b

6

4

5

4

Piperacillin-tazobactam^c

4

3

4

3

Appropriate combination therapy

3 (7.1)

0 (0.0)

1 (4.5)

0 (0.0)

Polymyxin B + aztreonam

2

0

1

0

Aztreonam + amikacin

1

0

-

-

Nonappropriate combination therapy

3 (7.1)

2 (66.7)

1 (4.5)

0

Aztreonam + ceftazidime + amikacin

1

1

-

-

Imipenem + ceftazidime

1

0

1

0

Imipenem + ciprofloxacin

1

1

-

-

Nonappropriate monotherapy

17 (40.5)

12 (70.6)

8 (36.4)

8 (100)

Cefepime

7

5

3

3

Meropenem

6

3

2

2

Imipenem

2

2

2

2

Ceftazidime

1

1

1

1

Amikacin

1

1

-

-

Without therapy

1 (2.4)

1 (100)

-

-

^aThe association of in vitro nonsusceptible antibiotics were used in three patients: ceftazidime (one patient), cefepime (one patient), and ceftazidime + amikacin (one patient); all were survivors. ^bOne patient received the association of cefepime (in vitro nonsusceptible); survivor. ^cOne patient received the association of ciprofloxacin (in vitro nonsusceptible); nonsurvivor.

Zavascki et al. Critical Care 2006 10:R114   doi:10.1186/cc5006